BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12643008)

  • 1. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
    Skeel RT; Huang J; Manola J; Wilding G; Dreicer R; Walker P; Muggia F; Crawford ED; Dutcher JP; Loehrer PJ
    Cancer Invest; 2003; 21(1):41-6. PubMed ID: 12643008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin.
    Lippman SM; Parkinson DR; Itri LM; Weber RS; Schantz SP; Ota DM; Schusterman MA; Krakoff IH; Gutterman JU; Hong WK
    J Natl Cancer Inst; 1992 Feb; 84(4):235-41. PubMed ID: 1734084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.
    Enzinger PC; Ilson DH; Saltz LB; Martin LK; Kelsen DP
    Cancer; 1999 Mar; 85(6):1213-7. PubMed ID: 10189124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
    Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Holdener E; Krakoff IH
    J Natl Cancer Inst; 1992 Feb; 84(4):241-5. PubMed ID: 1734085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon.
    Dunst J; Hänsgen G; Lautenschläger C; Füchsel G; Becker A
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):367-73. PubMed ID: 10030263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers.
    Dunst J; Hänsgen G; Krause U; Füchsel G; Köhler U; Becker A
    Strahlenther Onkol; 1998 Nov; 174(11):571-4. PubMed ID: 9830438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
    Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
    J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.
    Slabber CF; Falkson G; Burger W; Schoeman L
    Invest New Drugs; 1996; 14(4):391-4. PubMed ID: 9157075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva].
    Römisch M; Meier W; Kimmig R; Hepp H
    Geburtshilfe Frauenheilkd; 1996 Oct; 56(10):520-4. PubMed ID: 9036064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix.
    Hallum AV; Alberts DS; Lippman SM; Inclan L; Shamdas GJ; Childers JM; Surwit EA; Modiano M; Hatch KD
    Gynecol Oncol; 1995 Mar; 56(3):382-6. PubMed ID: 7705672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
    Wadler S; Schwartz EL; Haynes H; Rameau R; Quish A; Mandeli J; Gallagher R; Hallam S; Fields A; Goldberg G; McGill F; Jennings S; Wallach RC; Runowicz CD
    Cancer; 1997 Apr; 79(8):1574-80. PubMed ID: 9118041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
    Rinaldi DA; Lippman SM; Burris HA; Chou C; Von Hoff DD; Hong WK
    Anticancer Drugs; 1993 Feb; 4(1):33-6. PubMed ID: 8457712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.
    Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Massimini G; Holdener EE; Krakoff IH
    J Natl Cancer Inst; 1993 Mar; 85(6):499-500. PubMed ID: 8445678
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.
    Pazdur R; Bready B; Ajani JA; Abbruzzese JL; Markowitz A; Sugarman S; Jones D; Levin B
    Am J Clin Oncol; 1995 Oct; 18(5):436-8. PubMed ID: 7572763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
    Vaishampayan U; Flaherty L; Du W; Hussain M
    Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
    Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G
    Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
    J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of alpha-interferon 2a (alpha-IFN 2a) and 13-cis-retinoic acid (13cRA) in recurrent, pre-treated squamous-cell carcinoma of head and neck (SCCHN).
    Toma S; Airoldi M; Palumbo R; Raffo P; Bumma C
    Int J Cancer; 1997 Feb; 70(4):491-3. PubMed ID: 9033664
    [No Abstract]   [Full Text] [Related]  

  • 20. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma.
    Jaremtchuk AV; Aman EF; Ponce W; Zarbá JJ; Ferro AM; Alvarez R; Vigo SA
    Am J Clin Oncol; 2002 Apr; 25(2):123-5. PubMed ID: 11943887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.